Laboratory of Medical Immunology, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Front Immunol. 2019 Dec 3;10:2839. doi: 10.3389/fimmu.2019.02839. eCollection 2019.
Regulatory T cells (Treg) are well-known for their immune regulatory potential and are essential for maintaining immune homeostasis. The rationale of Treg-based immunotherapy for treating autoimmunity and transplant rejection is to tip the immune balance of effector T cell-mediated immune activation and Treg-mediated immune inhibition in favor of Treg cells, either through endogenous Treg expansion strategies or adoptive transfer of expanded Treg. Compelling evidence indicates that Treg show properties of phenotypic heterogeneity and instability, which has caused considerable debate in the field regarding their correct use. Consequently, for further optimization of Treg-based immunotherapy, it is vital to further our understanding of Treg proliferative, migratory, and suppressive behavior. It is increasingly appreciated that the functional profile of immune cells is highly dependent on their metabolic state. Although the metabolic profiles of effector T cells are progressively understood, little is known on Treg in this respect. The objective of this review is to outline the current knowledge of human Treg metabolic profiles associated with the regulation of Treg functionality. As such information on human Treg is still limited, where information was lacking, we included insightful findings from mouse studies. To assess the available evidence on metabolic pathways involved in Treg functionality, PubMed, and Embase were searched for articles in English indexed before April 28th, 2019 using "regulatory T lymphocyte," "cell metabolism," "cell proliferation," "migration," "suppressor function," and related search terms. Removal of duplicates and search of the references was performed manually. We discerned that while glycolysis fuels the biosynthetic and bioenergetic needs necessary for proliferation and migration of human Treg, suppressive capacity is mainly maintained by oxidative metabolism. Based on the knowledge of metabolic differences between Treg and non-Treg cells, we additionally discuss and propose ways of how human Treg metabolism could be exploited for the betterment of tolerance-inducing therapies.
调节性 T 细胞(Treg)因其免疫调节潜能而闻名,对于维持免疫稳态至关重要。基于 Treg 的免疫疗法治疗自身免疫和移植排斥的原理是通过内源性 Treg 扩增策略或过继转移扩增的 Treg,使效应 T 细胞介导的免疫激活与 Treg 介导的免疫抑制之间的免疫平衡向 Treg 倾斜。令人信服的证据表明,Treg 表现出表型异质性和不稳定性的特征,这在该领域引起了关于其正确使用的相当大的争论。因此,为了进一步优化基于 Treg 的免疫疗法,深入了解 Treg 的增殖、迁移和抑制作用至关重要。人们越来越认识到,免疫细胞的功能特征高度依赖于其代谢状态。尽管效应 T 细胞的代谢特征逐渐得到了解,但在这方面对 Treg 的了解甚少。本综述的目的是概述与 Treg 功能调节相关的人类 Treg 代谢特征的最新知识。由于有关人类 Treg 的信息仍然有限,在信息缺失的情况下,我们纳入了来自小鼠研究的有见地的发现。为了评估与 Treg 功能相关的代谢途径的现有证据,我们在 PubMed 和 Embase 上搜索了截至 2019 年 4 月 28 日之前以英文发表的文章,使用了“调节性 T 淋巴细胞”、“细胞代谢”、“细胞增殖”、“迁移”、“抑制功能”和相关搜索词。通过手动去除重复项和搜索参考文献来进行。我们发现,虽然糖酵解为人类 Treg 的增殖和迁移提供了必要的生物合成和生物能量需求,但抑制能力主要由氧化代谢维持。基于 Treg 和非 Treg 细胞之间代谢差异的知识,我们还讨论并提出了如何利用人类 Treg 代谢来改善诱导耐受的治疗方法。